WallStreetZenWallStreetZen

NASDAQ: FLNA
Filana Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their FLNA stock forecasts and price targets.

Forecast return on equity

Is FLNA forecast to generate an efficient return?

Company
N/A
Industry
66.25%
Market
172.91%

Forecast return on assets

Is FLNA forecast to generate an efficient return on assets?

Company
N/A
Industry
30.34%

FLNA earnings per share forecast

What is FLNA's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.24
Avg 2 year Forecast
$9.18

FLNA revenue forecast

What is FLNA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

FLNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FLNA$1.56N/AN/A
MAIA$1.24N/AN/A
PLRX$1.21$2.67+120.41%Buy
ICCC$8.25N/AN/A
ACET$7.93$63.50+700.76%Strong Buy
View Top Biotech Stocks

Filana Therapeutics Stock Forecast FAQ

What is FLNA's earnings growth forecast for 2026-2027?

(NASDAQ: FLNA) Filana Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.62%.

Filana Therapeutics's earnings in 2026 is -$90,973,000.On average, 3 Wall Street analysts forecast FLNA's earnings for 2026 to be -$60,114,346, with the lowest FLNA earnings forecast at -$57,756,920, and the highest FLNA earnings forecast at -$61,882,415.

In 2027, FLNA is forecast to generate $443,466,485 in earnings, with the lowest earnings forecast at $426,075,643 and the highest earnings forecast at $456,509,617.

If you're new to stock investing, here's how to buy Filana Therapeutics stock.

What is FLNA's revenue growth forecast for 2026-2028?

(NASDAQ: FLNA) Filana Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.35%.

Filana Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast FLNA's revenue for 2026 to be $0, with the lowest FLNA revenue forecast at $0, and the highest FLNA revenue forecast at $0. On average, 3 Wall Street analysts forecast FLNA's revenue for 2027 to be $0, with the lowest FLNA revenue forecast at $0, and the highest FLNA revenue forecast at $0.

In 2028, FLNA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is FLNA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: FLNA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 30.34%.

What is FLNA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: FLNA) Filana Therapeutics's current Earnings Per Share (EPS) is -$1.88. On average, analysts forecast that FLNA's EPS will be -$1.24 for 2026, with the lowest EPS forecast at -$1.20, and the highest EPS forecast at -$1.28. In 2027, FLNA's EPS is forecast to hit $9.18 (min: $8.82, max: $9.45).

What is FLNA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: FLNA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.